A composition and its application in preparing medicine for treating inflammation-related diseases

Abstract

The present invention relates to the field of medical technology, and in particular to a composition and its application in the preparation of drugs for treating inflammation-related diseases. The composition consists of polydatin and rhein. At least one of naringin, glycyrrhizic acid and liquiritin is also added to the composition. The present invention also discloses the application of the above composition in the preparation of drugs for treating inflammation-related diseases. The present invention finds the synergistic effect of polydatin and rhein, and the synergistic effect of the two has more significant anti-inflammatory effect than the single effect. The composition of the present invention can effectively inhibit the weight loss of mice infected with influenza A (H1N1) virus, inhibit the expression of inflammatory factors, and significantly improve the lung symptoms of infected mice, so that it can be used to treat pneumonia caused by influenza A (H1N1) virus.

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a composition and its application in preparing medicine for treating inflammation-related diseases. Background Art

[0002] Respiratory diseases are a type of common and frequently occurring clinical diseases, mainly including chronic pharyngitis, asthma, chronic obstructive pulmonary disease, pneumonia (bacterial pneumonia, viral pneumonia), pulmonary fibrosis, etc. The prevalence rate is increasing year by year, and it is becoming a serious problem affecting public health. Basic research shows that the common pathogenic mechanisms of various respiratory diseases include apoptosis and inflammatory response. Apoptosis refers to the active and orderly cell death produced by gene regulation under physiological or pathological conditions in order to maintain the homeostasis of its own internal environment. Its morphological characteristic is the formation of apoptotic bodies. The inflammatory response causes the body to react to tissue cells caused by pathogenic microorganism infection, trauma, allergic reaction, etc. The essence of the inflammatory response is a defensive response of the body.

[0003] Influenza virus is an enveloped RNA virus belonging to the family Orthomyxoviridae. It is divided into three types based on the antigenic differences of its nucleoprotein. The antigenic differences of its nucleoprotein mainly exist in the genome structure, polypeptide composition, infectivity and pathogenicity. Most influenza viruses are in the host cell nucleus, and their genome forms mature virus particles through the plasma membrane or organelle membrane buds. Influenza virus infection and viral replication mainly occur in respiratory epithelial cells, but it often causes local inflammation and systemic reactions. The body's response is mainly related to the activation of inflammatory cytokines, chemokines, adhesion molecules and microplasmin expression cassettes.

[0004] Chinese patent CN113713059A discloses a use of Xuanfei Baidu Recipe for preparing a drug for preventing and / or treating pneumonia caused by influenza A (H1N1) virus. The Xuanfei Baidu Recipe comprises the following ingredients by weight: 5-7 parts of raw ephedra, 28-32 parts of raw gypsum, 28-32 parts of raw coix seeds, 13-17 parts of bitter almonds, 8-12 parts of atractylodes, 13-17 parts of patchouli, 10-14 parts of artemisia annua, 28-32 parts of dried reed root, 13-17 parts of tangerine peel, 18-22 parts of knotweed, 28-32 parts of verbena, 13-17 parts of scutellaria baicalensis, and 8-12 parts of raw liquorice. The Xuanfei Baidu Recipe in the application can effectively reduce the viral load of influenza A (H1N1) virus, reduce the expression of pro-inflammatory factors and / or promote the expression of anti-inflammatory factors in infected individuals, and further reduce the infiltration of inflammatory cells in the alveoli and the thickening of the alveolar wall, so it can be used to prevent and / or treat pneumonia caused by influenza A (H1N1) virus. However, it mainly works in the form of a combination.

[0005] Chinese patent CN112245543A discloses a traditional Chinese medicine for clearing the lungs and eliminating toxins, which is made of the following raw materials in parts by weight: 110-190 parts of ephedra, 460-540 parts of knotweed, 330-420 parts of bitter almonds, 710-790 parts of verbena, 710-790 parts of gypsum, 710-790 parts of reed rhizome, 710-790 parts of coix seed, 330-420 parts of scutellaria baicalensis, 210-290 parts of atractylodes, 330-420 parts of tangerine peel, 330-420 parts of patchouli, 210-290 parts of licorice, and 250-350 parts of artemisia annua. The active extracts and Chinese medicine compositions of the present invention can improve the ability of the patient's immune system to fight coronavirus, alleviate or eliminate one or more symptoms of the patient, reduce the chance of mild symptoms turning into severe symptoms, increase the chance of severe symptoms turning into common or mild symptoms, shorten the time for patients to recover, shorten the course of the disease, and make nucleic acid turn negative faster. However, the Chinese medicine components need to be extracted during the preparation process, and the operation is relatively complicated.

[0006] Therefore, in order to better treat inflammation-related diseases, it is extremely important to develop a drug with small toxic side effects, significant efficacy and simple preparation for the treatment of inflammation-related diseases. Summary of the invention

[0007] In view of the above-mentioned problems, the present invention aims to provide a composition and its use in preparing a drug for treating inflammation-related diseases.

[0008] To achieve the above-mentioned object of the invention, the technical solution of the present invention is as follows:

[0009] In one aspect, the present invention provides a composition for treating inflammation, the composition consisting of polydatin and rhamnolide.

[0010] Preferably, the composition consists of the following ingredients in parts by weight: 2-4 parts of polydatin and 1-4 parts of rhein.

[0011] Preferably, at least one of naringin, glycyrrhizic acid and liquiritin is also added to the composition.

[0012] More preferably, the composition further comprises at least one of 25-35 parts of naringin, 3-5 parts of glycyrrhizic acid, and 1-4 parts of liquiritin, in parts by weight.

[0013] Preferably, the composition consists of the following ingredients in parts by weight: 25-35 parts of naringin, 3-5 parts of glycyrrhizic acid, 2-4 parts of polydatin, 1-4 parts of liquiritin, and 1-4 parts of rhein.

[0014] Further preferably, the composition consists of the following ingredients in parts by weight: 30 parts of naringin, 4.2 parts of glycyrrhizic acid, 3.9 parts of polydatin, 2.6 parts of liquiritin, and 2 parts of rhein.

[0015] In another aspect, the present invention provides use of the above composition in preparing a drug for treating inflammation-related diseases.

[0016] Preferably, the inflammation is caused by influenza virus.

[0017] Further preferably, the influenza virus includes influenza A virus, influenza B virus, influenza C virus and Spanish flu virus.

[0018] Still more preferably, the influenza virus is influenza A virus.

[0019] Preferably, the influenza A virus includes influenza A (H1N1) virus, influenza A (H3N2) virus, influenza A (H5N1) virus and influenza A (H7N9) virus.

[0020] More preferably, the influenza A virus is influenza A (H1N1) virus.

[0021] Preferably, the drug further comprises a medically acceptable carrier.

[0022] Further preferably, the medically acceptable carrier is selected from at least one of an emulsifier, a filler, a binder, a lubricant, a disintegrant, a thickener, a surfactant, and a solubilizing agent.

[0023] Specifically, the emulsifier is selected from at least one of polysorbate, polyglycerol ester, sodium stearoyl lactylate, calcium stearoyl lactylate, and diacetyl tartaric acid monoglyceride.

[0024] Specifically, the filler is selected from at least one of mannitol, lactitol, microcrystalline cellulose, powdered cellulose, and silicified microcrystalline cellulose.

[0025] Specifically, the adhesive is selected from at least one of hydroxypropyl methylcellulose, hydroxypropyl cellulose, povidone, and pre-cured starch.

[0026] Specifically, the lubricant is selected from at least one of magnesium stearate, calcium stearate, zinc stearate, sodium stearate, stearic acid, sodium stearyl fumarate, polyethylene glycol, and sodium lauryl sulfate.

[0027] Specifically, the disintegrant is selected from at least one of cross-linked sodium carboxymethyl cellulose, cross-linked polyvinyl pyrrolidone, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, dry starch, and polyclidinium potassium.

[0028] Specifically, the thickener is at least one selected from methyl cellulose, carboxymethyl cellulose, ethyl cellulose, hydroxyethyl cellulose, cyanoethyl cellulose, hydroxypropyl cellulose and hydroxypropyl methyl cellulose.

[0029] Specifically, the surfactant is selected from at least one of lauryl glucoside, sodium lauryl sulfate, dioctyl sodium sulfosuccinate, sodium dodecylbenzene sulfonate, and sodium glycocholate.

[0030] Specifically, the co-solvent is selected from at least one of organic acids and salts thereof, amide and amine compounds, inorganic salts, polyethylene glycol, povidone, and glycerol.

[0031] Preferably, the composition is used in combination with other active ingredients.

[0032] Further preferably, other active ingredients include but are not limited to flavonoids, alkaloids, and polysaccharides.

[0033] Still further preferably, the flavonoids include but are not limited to Forsythia suspensa, baicalin, baicalein, wogonin, baicalin, quercetin, isorhamnetin, Bupleurum chinense, and Licorice.

[0034] Still further preferably, the alkaloids include but are not limited to sophora flavescens, acantholine, berberine, and isotetrandrine.

[0035] Still further preferably, the polysaccharides include but are not limited to ginseng polysaccharide, astragalus polysaccharide, laver polysaccharide, and lentinan polysaccharide.

[0036] Preferably, the dosage form of the drug is selected from at least one of capsules, tablets, lozenges, troches, granules, powders, elixirs, syrups, emulsions, dispersions, and suspensions.

[0037] The medicine of the present invention comprises a composition as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants. The active ingredient can be orally administered in a solid dosage form or a liquid dosage form, such as capsules, tablets, lozenges, lozenges, granules and powders, and the liquid dosage form is such as elixir, syrup, emulsion, dispersion and suspension. The active ingredient can also be administered parenterally in a sterile liquid dosage form such as a dispersion, suspension or solution. Other dosage forms that can be used to administer the active ingredient include ointments, creams, drops, transdermal patches or powders for topical administration; ophthalmic solutions or suspension forms for eye administration, i.e. eye drops; sprays or powder compositions for inhalation or intranasal administration, or creams, ointments, sprays or suppositories for rectal or vaginal administration. Gelatin capsules contain active ingredients and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, etc. Similar diluents can be used to prepare compressed tablets. Tablets and capsules can be prepared into sustained-release products to provide sustained release of medicine within a few hours. Compressed tablets can be coated with sugar or film to cover any unpleasant taste and protect the tablet from air, or can be enteric-coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can include coloring agents and flavoring agents to increase patient acceptance. Generally speaking, water, suitable oil, saline, dextrose (glucose) aqueous solution and related sugar solution and glycols such as propylene glycol or polyethylene glycol are the carriers of suitable parenteral solutions. The solution for parenteral administration preferably includes water-soluble salts of active ingredients, suitable stabilizers and the buffer substance used as required.

[0038] Compared with the prior art, the present invention has the following beneficial effects:

[0039] (1) The present invention discovered the synergistic effect of polydatin and rhamnolide, which have more significant anti-inflammatory effects than either of the two alone.

[0040] (2) The composition of the present invention can effectively inhibit the weight loss of mice infected with influenza A (H1N1) virus, inhibit the expression of inflammatory factors, and significantly improve the lung symptoms of infected mice, and thus can be used to treat pneumonia caused by influenza A (H1N1) virus. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 The effect of the combination and other compatible components in the LPS-stimulated inflammation model. In the figure, compared with the control group, ## p<0.01, compared with LPS group, * p<0.05, ** p<0.01.

[0042] Figure 2The effect of the combination and other compatible components in the inflammasome activation model. In the figure, compared with the LPS group, ## p<0.01, compared with LPS+ATP group, * p<0.05, ** p<0.01.

[0043] Figure 3 The figure is a graph showing the anti-inflammatory activity of polydatin and rhamnolide and their synergistic effect. In the figure, "+" represents the addition of the ingredient, and "-" represents the absence of the ingredient.

[0044] Figure 4 The weight changes of mice.

[0045] Figure 5 The following are the results of HE staining of lung tissues of mice in each group 3 days after administration.

[0046] Figure 6 The expression of pro-inflammatory cytokine TNF-α in mouse serum. *** p<0.001.

[0047] Figure 7 The expression of pro-inflammatory cytokine IL-1β in mouse serum. ** p<0.01, *** p<0.001.

[0048] Figure 8 The expression of pro-inflammatory cytokine IL-6 in mouse serum. ** p<0.01, *** p<0.001. DETAILED DESCRIPTION

[0049] In order to make the technical means, creative features, purpose and efficacy of the present invention easy to understand, the present invention is further explained in conjunction with specific embodiments below, but the following embodiments are only preferred embodiments of the present invention, not all. Based on the embodiments in the implementation mode, other embodiments obtained by those skilled in the art without creative work all belong to the protection scope of the present invention. In the following embodiments, unless otherwise specified, the operating methods used are conventional operating methods, the equipment used are conventional equipment, and the equipment materials used in each embodiment are the same.

[0050] The manufacturer and product number of the raw material components:

[0051] Naringin: purchased from Chengdu Desit Biotechnology Co., Ltd., catalog number DY0099-0020;

[0052] Glycyrrhizic acid: purchased from Chengdu Desit Biotechnology Co., Ltd., catalog number DG0006-0020;

[0053] Polydatin: purchased from Chengdu Desite Biotechnology Co., Ltd., catalog number DH0038-0020;

[0054] Liquorice glycoside: purchased from Chengdu Desit Biotechnology Co., Ltd., catalog number DG0009-0020;

[0055] Rhein: purchased from Chengdu Desite Biotechnology Co., Ltd., catalog number DD0030-0020;

[0056] Methyl 3,5-dinitrobenzoate: purchased from Sigma, USA, product number 386367;

[0057] H1N1 murine lung influenza adapted strain A / Puerto Rico / 8 / 1934 was purchased from Genex, USA;

[0058] Preparation method of naringin: 10 mg of naringin is added to 1 mL of DMSO.

[0059] Preparation method of glycyrrhizic acid: 10 mg of glycyrrhizic acid is added to 1 mL of DMSO.

[0060] The preparation method of polydatin is as follows: 10 mg of polydatin is added to 1 mL of DMSO.

[0061] Preparation method of liquiritin: 10 mg of liquiritin is added to 1 mL of DMSO.

[0062] The preparation method of emodin is as follows: 10 mg of emodin is added to 1 mL of DMSO.

[0063] Example 1 Preparation of the composition

[0064] The composition is prepared by the following method: 30 μL of 10 mg / mL liquiritin, 4.2 μL of 10 mg / mL glycyrrhizic acid, 3.9 μL of 10 mg / mL polydatin, 2.6 μL of 10 mg / mL liquiritin, 2 μL of 10 mg / mL rhamnolide and 7.3 μL of DMSO.

[0065] Experimental Example 1

[0066] In order to explore the compatibility rules of the combination and its synergistic effect, we removed certain chemical components from the complete combination (referred to as Comb1), as shown in Table 1. We also evaluated the anti-inflammatory activity of the combination components after removing the compounds. Through model verification, we found that the activity of the combination Comb1-a and the combination Comb1-c decreased in the LPS-stimulated inflammation model, and the activity of the combination Comb1-a decreased in the inflammasome activation model. Figure 1-Figure 2 As shown in the figure, it is inferred that polydatin and emodin are the main anti-inflammatory active compounds, and emodin is the main anti-inflammatory body compound. Subsequent experiments also verified this inference and found the synergistic effect of polydatin and emodin. The synergistic effect of the two has more significant anti-inflammatory effect than that of each other. The experimental results are shown in Figure 3 .

[0067] Table 1

[0068] Serial number Naringin Glycyrrhizic acid Polydatin Licorice glycoside Rhein Comb1 + + + + + Comb1-a + + + + - Comb1-b + + + - + Comb1-c + + - + + Comb1-d + - + + + Comb1-e - + + + +

[0069] Note: + represents the addition of the component; “-” represents the non-addition of the component.

[0070] Experimental Example 2 Effect of the composition on mice infected with influenza A (H1N1) virus

[0071] 1. Calculation of drug dosage for mouse model

[0072] The original formula has an ointment yield of 12.6%, the commonly used human oral crude drug dosage is 238g, the equivalent dose ratio of mice to humans is 0.0026:1, and according to 20g per mouse, the equivalent dose of mice is 238×0.126×0.0026 / 0.02=3.89844g / kg, and 3.9g / kg is set as the equivalent dose of the whole formula. The combination accounts for 10% of the whole formula.

[0073] 2. Experimental Animal Grouping:

[0074] Low-dose group of the combination: dosage: 0.39 g / kg;

[0075] High-dose group of the composition: dosage: 0.78 g / kg.

[0076] 3. Establishment of a mouse model of pneumonia caused by influenza A (H1N1) virus

[0077] A total of 65 healthy 8-week-old C57BL / 6J female mice (Beijing Weitonglihua Experimental Animal Technology Co., Ltd.) with a body weight of (18-20) g were selected, and 13 mice were randomly selected as the control group. Each mouse was instilled with PBS through the nose, and the remaining mice were instilled with H1N1 murine lung influenza adapted strain A / Puerto Rico / 8 / 1934 (Genex, USA, hereinafter referred to as PR8) through the nose, and were randomly divided into a model group, a low-dose combination group (XFComb1L group), a high-dose combination group (XFComb1H) and a positive drug oseltamivir group. Among them, on the day of infection, the XFComb1L group was given 0.039g / ml of the composition Comb1 saline solution, the XFComb1H group was given 0.078g / ml of the composition Comb1 saline solution, the oseltamivir group was given 3.05mg / ml of oseltamivir saline solution, and the control group was given saline. Each group of mice was administered by gavage, 0.2mL per day, for 3 consecutive days; 6 mice were randomly selected from each group, and their body weight was monitored for 7 days from the first administration (or completion of infection); the remaining 7 mice were killed by cervical dislocation 3 days after administration, and blood samples and lung tissue samples were taken.

[0078] Detection Methods

[0079] HE staining experimental steps:

[0080] (1) Prepare paraffin sections of mouse lung tissue and dewax the paraffin sections to water: sequentially place the sections in xylene I for 20 min; xylene II for 20 min; anhydrous ethanol I for 5 min; anhydrous ethanol II for 5 min; 75% alcohol for 5 min; and wash with tap water.

[0081] (2) Hematoxylin staining: Stain the sections with hematoxylin solution for 3-5 min, wash with tap water, differentiate with differentiation solution, wash with tap water, reblue with bluing solution, and rinse with running water.

[0082] (3) Eosin staining: The sections were dehydrated in 85% and 95% graded alcohol for 5 min each, and then stained in eosin solution for 5 min.

[0083] (4) Dehydration and sealing: The sections were placed in anhydrous ethanol I for 5 min, anhydrous ethanol II for 5 min, anhydrous ethanol III for 5 min, xylene I for 5 min, and xylene II for 5 min to make them transparent, and then sealed with neutral gum.

[0084] (5) Microscope examination, image acquisition and analysis.

[0085] ELISA method was used to determine the content of TNF-α, IL-1β and IL-6 in mouse serum:

[0086] The levels of TNF-α, IL-1β and IL-6 in mouse serum were determined using ELISA kits 88-7324, 88-7013 and 88-7064 from Thermo Fisher Scientific. The specific steps are as follows:

[0087] (1) Prepare 1X Coating Buffer: Add 10X Coating Buffer into a 50 ml centrifuge tube containing ultrapure water and mix well.

[0088] (2) Prepare capture antibody coating solution (CA): dilute the capture antibody 250 times with 1X Coating Buffer. Add the capture antibody stock solution into a 15 ml centrifuge tube containing 1X Coating Buffer and mix well.

[0089] (3) Add 90 μl of capture antibody coating solution (CA) to each well, attach the membrane, and incubate overnight at 4°C.

[0090] (4) Prepare Wash Buffer: 250ul Tween TM Add 500 ml 1× PBS to -20 mL and mix well.

[0091] (5) Shake off the capture antibody coating solution (CA) in the 96-well plate, pat dry on absorbent paper, add 300ul Wash Buffer to each well, wash three times, each time for 1 min, and pat dry on absorbent paper.

[0092] (6) Prepare 1X ELISA / ELISPOT blocking buffer: Add 5X ELISA / ELISPOT to a 50 ml centrifuge tube containing pure water and mix well.

[0093] A B C D E F G H I Concentration (pg / ml) 1000 500 250 125 62.5 31.25 15.625 7.813 0 Standard product (ul) 200 100A 100B 100C 100D 100E 100F 100G 0 Blocking solution (ul) 0 100 100 100 100 100 100 100 100 Final volume (ul) 100 100 100 100 100 100 100 200 100

[0094] (7) Add 150 μl of 1X ELISA / ELISPOT blocking solution to each well, attach the membrane, and leave at room temperature for 1 hour.

[0095] (8) Prepare 1000 pg / ml mouse TNF-α, IL-1β and IL-6 standards: Add 700 μl of 1X ELISA / ELISPOT blocking buffer to a standard vial and dissolve all the powder.

[0096] (9) Dilute the sample with 1X ELISA / ELISPOT blocking buffer.

[0097] (10) Shake off the 1X ELISA / ELISPOT blocking buffer in the wells and wash once with Wash Buffer.

[0098] (11) Load the sample, attach the membrane, and leave at room temperature for 2 h.

[0099] (12) Prepare 1× Detection Antibody (DA): Add 250× Detection Antibody into a 15 ml centrifuge tube containing 1× ELISA / ELISPOT blocking buffer and mix well.

[0100] (13) Shake off the liquid in the 96-well plate, pat dry on absorbent paper, add 300 μl Wash Buffer to each well, wash three times, leaving the plate for 1 min each time, and pat dry on absorbent paper.

[0101] (14) Add 90 μl of 1× Detection Antibody (DA) to each well, attach the membrane, and leave at room temperature for 1 h.

[0102] (15) Prepare 1× Streptavidin-HRP: Add HRP concentrate (100×) into a 15 ml centrifuge tube containing 1× ELISA / ELISPOT blocking buffer and mix well.

[0103] (16) Shake off the liquid in the 96-well plate, pat dry on absorbent paper, add 300 μl Wash Buffer to each well, wash three times, leaving the plate for 1 min each time. Pat dry on absorbent paper each time, and pat dry thoroughly on the last time.

[0104] (17) Add 90 μl of 1× Streptavidin-HRP to each well, attach the membrane, and leave at room temperature for 30 min.

[0105] (18) Shake off the liquid in the 96-well plate, pat dry on absorbent paper, add 300 μl Wash Buffer to each well, wash five times, leaving the plate for 1 min each time, and pat dry on absorbent paper.

[0106] (19) Add 90 μl of 1X TMB solution to each well (protect from light), attach the membrane, and leave at room temperature for 15 min.

[0107] (20) Add 90 μL Top Solution to each well (protect from light).

[0108] (21) Final value = OD450 - OD570.

[0109] Experimental results:

[0110] After the mice were modeled and divided into groups and given medication, the weight changes of mice in each group were observed for 7 days. Figure 4As shown, after 3 days of administration, the HE staining results of the lung tissues of mice in each group were as follows Figure 5 shown.

[0111] from Figure 4 It can be seen that compared with the control group, the body weight of mice in the model group was significantly reduced. Compared with the model group, the composition Comb1-3 can significantly inhibit the reduction of body weight of mice infected with influenza virus.

[0112] from Figure 5 It can be seen that the alveolar structure of the control group is intact, the morphology is regular, and there is no inflammatory cell infiltration in the surrounding tissues. The model group mice have obvious inflammatory cell infiltration in the alveoli and thickening of the alveolar wall; compared with the model group, the composition can reduce the infiltration of inflammatory cells in the alveoli and the thickening of the alveolar wall after administration. The above results show that the composition Comb1 of the present application can significantly improve the lung symptoms of infected mice.

[0113] Effect of the composition on the release of inflammatory factors in mice infected with influenza A (H1N1) virus:

[0114] The expression of proinflammatory cytokines TNF-α, IL-1β, and IL-6 in mouse serum. Figure 6-Figure 8 As shown, from Figure 6-Figure 8 It can be seen that compared with the control group, the levels of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 in the serum of mice in the model group were significantly increased (P < 0.01). Compared with the model group, the composition can significantly reduce the expression of TNF-α, IL-1β, and IL-6 in the alveolar lavage fluid and serum of mice (P < 0.01). This shows that the composition of the present application can reduce the expression of pro-inflammatory factors in the serum of mice.

[0115] The above examples illustrate that the composition of the present application can effectively inhibit the weight loss of mice infected with influenza A (H1N1) virus, inhibit the expression of inflammatory factors, and significantly improve the lung symptoms of infected mice, thereby being used to treat pneumonia caused by influenza A (H1N1) virus.

[0116] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A composition for treating pneumonia caused by influenza A (H1N1) virus, characterized in that: The composition consists of the following components in parts by weight: 30 parts of naringin, 4.2 parts of glycyrrhizic acid, 3.9 parts of polydatin, 2.6 parts of liquiritin and 2 parts of rhein.

2. Use of the composition according to claim 1 in the preparation of a medicament for treating pneumonia caused by influenza A (H1N1) virus.

Images